Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Anthem, Inc.    ANTM


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Anthem : Announces Research Study with Apple Watch to Help Improve Asthma Management

share with twitter share with LinkedIn share with facebook
09/16/2020 | 10:05am EDT

The study, to be led by the University of California, Irvine, investigates how digital tools can aid clinical outcomes

Anthem, Inc. announced today a new study that examines how the use of everyday devices, like Apple Watch and iPhone, may help individuals with asthma better self-manage their condition for improved clinical outcomes. The virtual study is being conducted by University of California, Irvine (UCI) and was designed in collaboration with Apple, Inc. CareEvolution is the study technology partner responsible for building the study app and enabling collection of the study data.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005283/en/

Anthem, Inc. announced today a new study that examines how the use of everyday devices, like Apple Watch and iPhone, may help individuals with asthma better self-manage their condition for improved clinical outcomes. (Graphic: Business Wire)

Anthem, Inc. announced today a new study that examines how the use of everyday devices, like Apple Watch and iPhone, may help individuals with asthma better self-manage their condition for improved clinical outcomes. (Graphic: Business Wire)

Launching in the fall, the two-year, randomized controlled study will enroll participants from Anthem-affiliated health plans who have been clinically diagnosed with asthma. Nearly 25 million Americans are currently diagnosed with some form of the chronic condition, and, when uncontrolled, asthma can lead to permanent lung damage, hospitalizations and even premature death. Additionally, nearly 1.8 million emergency department visits each year are counted as a result of asthma attacks.

“As part of our mission of improving people’s lives, we are making it easier for consumers to proactively manage their health through our digital-first approach to delivering healthcare solutions and services,” said Rajeev Ronanki, Chief Digital Officer at Anthem, Inc. “Millions of Americans are struggling with their asthma condition each day and we’re thrilled to collaborate with UCI, Apple and CareEvolution on studying new solutions.”

The primary goal of the study is to investigate clinical changes in outcomes associated with the use of the new digital tools in self-management of asthma. Additionally, the study will explore if data collected from everyday use devices such as iPhone and Apple Watch can help predict asthma exacerbation or serve as potential digital biomarkers of asthma control.

“Personalized medicine and improving the health of populations are based on similar principles. The human body contains critical information – data – necessary to diagnose and treat our patients,” said Dr. Steve Goldstein, vice chancellor for health affairs at UCI. “Through innovation and emerging technologies, we are able to harness that data, and by coupling it with an individual’s environment and experiences, chart pathways to lifelong health and well-being. Public-private collaborations like this one with UCI, Anthem and Apple, are fueled by the passion to serve and shared entrepreneurial spirit, and are helping us establish new standards of whole-person care for our patients.”

“The Digital Asthma Study brings together Apple Watch’s innovative technology with an engaging app-based self-management experience to investigate how consumers can better manage and control a prevalent condition,” says Myoung Cha, Apple’s Head of Health Strategic Initiatives. “We hope this study can help the medical community produce new insights about asthma control and can identify effective digital tools that can help empower people around the world to better manage their condition.”

About the Study

Eligible participants will be invited to enroll in the study. Participants who choose to enroll in the study will receive a BedditTM Sleep Monitor and an Apple Watch.

While there is no cure for asthma, studies have shown that many people can improve their symptoms and reduce exacerbation risk through self-management behaviors including avoiding triggers - such as pollen, mold or smoke - medication adherence, and correct inhaler technique.1 However, asthma self-management is often far from ideal, with some data suggesting that less than 50 percent of individuals with asthma are well-controlled.2 Scalable and effective solutions are needed to empower patients to improve asthma self-management and reduce the need for costly asthma care.3

To investigate the impact of digital intervention on asthma symptoms and healthcare utilization, the active group of the study will have access to the digital asthma tool, designed for the study. The digital asthma tool includes daily symptom and trigger tracking to provide awareness of asthma control and personalized nudges based on changes in signals from their Apple Watch including activity, heart rate, the new Blood Oxygen feature and other health metrics. Participants will also receive timely curated education materials and prescription refill resources.

Designed with patient privacy in mind, the study offers the participants complete control over their data, and transparency into how the data will be used and shared. Data will be stored on the participants’ device and shared through a direct, encrypted connection with CareEvolution.

About Anthem, Inc.

Anthem is a leading health benefits company dedicated to improving lives and communities, and making healthcare simpler. Through its affiliated companies, Anthem serves more than 106 million people, including more than 42 million within its family of health plans. We aim to be the most innovative, valuable and inclusive partner. For more information, please visit www.antheminc.com or follow @AnthemInc on Twitter.

About the University of California, Irvine

Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 222 degree programs. It’s located in one of the world’s safest and most economically vibrant communities and is Orange County’s second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visit www.uci.edu.



© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about ANTHEM, INC.
10/28GLOBAL MARKETS LIVE : Microsoft, Deutsche Bank, Sony…
10/28ANTHEM : tops 3Q forecasts as it absorbs big expense hit
10/28ANTHEM : Cuts 2020 Earnings Outlook Amid Covid-19 Uncertainty
10/28ANTHEM : 3Q Profit Falls, Revenue Rises
10/28Anthem sees higher costs, persisting uncertainty due to COVID-19; shares dip
10/28ANTHEM : 3Q Earnings Snapshot
10/28Health insurer Anthem quarterly profit slumps 81% on higher costs
10/28ANTHEM, INC. : Results of Operations and Financial Condition, Financial Statemen..
10/28ANTHEM : Reports Third Quarter Results, Reaffirms Commitment to Stakeholders Dur..
More news
Financials (USD)
Sales 2020 120 B - -
Net income 2020 4 909 M - -
Net Debt 2020 17 596 M - -
P/E ratio 2020 14,6x
Yield 2020 1,39%
Capitalization 67 961 M 67 961 M -
EV / Sales 2020 0,71x
EV / Sales 2021 0,65x
Nbr of Employees 70 600
Free-Float 99,0%
Duration : Period :
Anthem, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTHEM, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 24
Average target price 342,04 $
Last Close Price 273,26 $
Spread / Highest target 54,8%
Spread / Average Target 25,2%
Spread / Lowest Target 9,79%
EPS Revisions
Gail Koziara Boudreaux President, Chief Executive Officer & Director
Elizabeth E. Tallett Independent Chairman
John E. Gallina Chief Financial Officer & Executive Vice President
Ramiro G. Peru Independent Director
Julie Anne Hill Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTHEM, INC.-9.53%71 881
HUMANA INC.8.25%54 670